GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis
Europe - EPA:ALGEN - FR0004053510 - Common Stock
2.21 EUR
-0.02 (-0.9%)
Overall ALGEN gets a fundamental rating of 5 out of 10. We evaluated ALGEN against 75 industry peers in the Biotechnology industry. ALGEN has only an average score on both its financial health and profitability. ALGEN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year ALGEN was profitable.
ALGEN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ALGEN reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.96%, ALGEN is in the better half of the industry, outperforming 78.38% of the companies in the same industry.
ALGEN has a Return On Equity of 7.06%. This is in the better half of the industry: ALGEN outperforms 79.73% of its industry peers.
ALGEN has a Return On Invested Capital of 6.13%. This is amongst the best in the industry. ALGEN outperforms 83.78% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ALGEN is significantly below the industry average of 12.96%.
The 3 year average ROIC (5.56%) for ALGEN is below the current ROIC(6.13%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROIC | 6.13% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ALGEN (5.86%) is better than 81.08% of its industry peers.
ALGEN has a Operating Margin of 8.09%. This is in the better half of the industry: ALGEN outperforms 79.73% of its industry peers.
ALGEN's Gross Margin of 92.34% is amongst the best of the industry. ALGEN outperforms 87.84% of its industry peers.
In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ALGEN is destroying value.
Compared to 1 year ago, ALGEN has less shares outstanding
ALGEN has more shares outstanding than it did 5 years ago.
ALGEN has a better debt/assets ratio than last year.
2.2 Solvency
ALGEN has an Altman-Z score of 2.14. This is not the best score and indicates that ALGEN is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.14, ALGEN is in the better half of the industry, outperforming 70.27% of the companies in the same industry.
The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.41, ALGEN belongs to the best of the industry, outperforming 87.84% of the companies in the same industry.
ALGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
ALGEN has a Debt to Equity ratio (0.26) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Altman-Z | 2.14 |
ROIC/WACC0.88
WACC6.93%
2.3 Liquidity
A Current Ratio of 1.92 indicates that ALGEN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.92, ALGEN is in line with its industry, outperforming 45.95% of the companies in the same industry.
ALGEN has a Quick Ratio of 1.81. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.
ALGEN has a Quick ratio (1.81) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
ALGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.41%, which is quite good.
Looking at the last year, ALGEN shows a quite strong growth in Revenue. The Revenue has grown by 10.04% in the last year.
Measured over the past years, ALGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.46% on average per year.
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
3.2 Future
The Earnings Per Share is expected to decrease by 0.00% on average over the next years.
Based on estimates for the next years, ALGEN will show a quite strong growth in Revenue. The Revenue will grow by 10.37% on average per year.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.52, which indicates a very decent valuation of ALGEN.
ALGEN's Price/Earnings ratio is rather cheap when compared to the industry. ALGEN is cheaper than 89.19% of the companies in the same industry.
When comparing the Price/Earnings ratio of ALGEN to the average of the S&P500 Index (25.89), we can say ALGEN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.52 | ||
| Fwd PE | N/A |
4.2 Price Multiples
93.24% of the companies in the same industry are more expensive than ALGEN, based on the Enterprise Value to EBITDA ratio.
95.95% of the companies in the same industry are more expensive than ALGEN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.62 | ||
| EV/EBITDA | 3.71 |
4.3 Compensation for Growth
ALGEN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%
5. Dividend
5.1 Amount
No dividends for ALGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALGEN (11/14/2025, 7:00:00 PM)
2.21
-0.02 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners10.39%
Ins Owner ChangeN/A
Market Cap20.95M
Revenue(TTM)22.06M
Net Income(TTM)1.26M
Analysts86.67
Price Target6.02 (172.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.52 | ||
| Fwd PE | N/A | ||
| P/S | 0.98 | ||
| P/FCF | 4.62 | ||
| P/OCF | 3.03 | ||
| P/B | 1.18 | ||
| P/tB | 1.72 | ||
| EV/EBITDA | 3.71 |
EPS(TTM)0.21
EY9.5%
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.48
FCFY21.63%
OCF(TTM)0.73
OCFY32.97%
SpS2.26
BVpS1.88
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROCE | 7.62% | ||
| ROIC | 6.13% | ||
| ROICexc | 7.79% | ||
| ROICexgc | 11.35% | ||
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% | ||
| FCFM | 21.15% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score5
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Debt/EBITDA | 0.77 | ||
| Cap/Depr | 55.06% | ||
| Cap/Sales | 11.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 114.18% | ||
| Profit Quality | 360.76% | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 2.14 |
F-Score5
WACC6.93%
ROIC/WACC0.88
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y0.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y308.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1010.09%
OCF growth 3YN/A
OCF growth 5YN/A
GENOWAY SA / ALGEN.PA FAQ
Can you provide the ChartMill fundamental rating for GENOWAY SA?
ChartMill assigns a fundamental rating of 5 / 10 to ALGEN.PA.
Can you provide the valuation status for GENOWAY SA?
ChartMill assigns a valuation rating of 5 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Fairly Valued.
How profitable is GENOWAY SA (ALGEN.PA) stock?
GENOWAY SA (ALGEN.PA) has a profitability rating of 6 / 10.
How financially healthy is GENOWAY SA?
The financial health rating of GENOWAY SA (ALGEN.PA) is 6 / 10.